Therapy-related Myelodysplastic Syndrome: Models and Genetics

Overview

Journal Biol Blood Marrow Transplant

Date 2009 Oct 28

PMID 19857585

Citations 5

Authors

Timothy Graubert

Affiliations

Soon will be listed here.

Citing Articles

Secondary myelodysplastic syndromes identified via next-generation sequencing in a non-small cell lung cancer patient.

Feng Y, Chen X, Jiang K, Zhang D, Tao F, Ni D BMC Med Genomics. 2021; 14(1):299.

PMID: 34930266 PMC: 8691080. DOI: 10.1186/s12920-021-01147-y.

Hereditary cancer syndrome-associated pathogenic variants are common in patients with hematologic malignancies subsequent to primary solid cancer.

Oh J, Kim Y, Kim Y, Kim B, Park K, Nam S J Cancer. 2021; 12(14):4288-4294.

PMID: 34093829 PMC: 8176409. DOI: 10.7150/jca.54169.

Myelodysplastic Syndrome in Patients with Gastro-Pancreatic Malignancies: A Case Series and Review of Literature.

Godara A, Kumar A, Miller K, Saif M Cancer Med J. 2020; 4(2):52-59.

PMID: 32685937 PMC: 7367144.

Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study.

Sun L, Lin C, Lin M, Liang J, Kao C Medicine (Baltimore). 2015; 94(17):e737.

PMID: 25929909 PMC: 4603069. DOI: 10.1097/MD.0000000000000737.

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Tefferi A Mayo Clin Proc. 2010; 85(11):1042-5.

PMID: 20861462 PMC: 2966368. DOI: 10.4065/mcp.2010.0502.

References

Chen C, Lin L, Tang J, Ko B, Tsay W, Chou W . RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol. 2007; 139(3):405-14. DOI: 10.1111/j.1365-2141.2007.06811.x. View

Felix C, Walker A, Lange B, Williams T, Winick N, Cheung N . Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A. 1998; 95(22):13176-81. PMC: 23750. DOI: 10.1073/pnas.95.22.13176. View

Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E . The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 2002; 100(10):3761-6. DOI: 10.1182/blood-2002-04-1152. View

Papageorgio C, Seiter K, Feldman E . Therapy-related myelodysplastic syndrome in adults with neurofibromatosis. Leuk Lymphoma. 1999; 32(5-6):605-8. DOI: 10.3109/10428199909058420. View

Graubert T, Payton M, Shao J, Walgren R, Monahan R, Frater J . Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One. 2009; 4(2):e4583. PMC: 2642994. DOI: 10.1371/journal.pone.0004583. View

Funk R, Maxwell T, Izumi M, Edwin D, Kreisel F, Ley T . Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. Blood. 2008; 112(4):1434-42. PMC: 2515115. DOI: 10.1182/blood-2008-01-132084. View

Allan J, Smith A, Wheatley K, Hills R, Travis L, Hill D . Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood. 2004; 104(13):3872-7. DOI: 10.1182/blood-2004-06-2161. View

Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S . A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007; 92(6):744-52. DOI: 10.3324/haematol.10869. View

Allan J, Wild C, Rollinson S, Willett E, Moorman A, Dovey G . Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A. 2001; 98(20):11592-7. PMC: 58774. DOI: 10.1073/pnas.191211198. View

10.

Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T . Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2003; 18(1):120-5. DOI: 10.1038/sj.leu.2403187. View

11.

Chen C, Lin L, Tang J, Tsay W, Chang H, Yeh Y . Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia. 2006; 20(6):1155-8. DOI: 10.1038/sj.leu.2404190. View

12.

Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-Lefebvre P . High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005; 105(10):3817-23. DOI: 10.1182/blood-2004-10-3920. View

13.

Pedersen-Bjergaard J, Andersen M, Andersen M, Christiansen D . Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008; 22(2):240-8. DOI: 10.1038/sj.leu.2405078. View

14.

Abruzzese E, Radford J, Miller J, Vredenburgh J, Rao P, Pettenati M . Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 1999; 94(5):1814-9. View

15.

Chao R, Pyzel U, Fridlyand J, Kuo Y, Teel L, Haaga J . Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell. 2005; 8(4):337-48. DOI: 10.1016/j.ccr.2005.08.011. View

16.

Hake C, Graubert T, Fenske T . Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?. Bone Marrow Transplant. 2006; 39(2):59-70. DOI: 10.1038/sj.bmt.1705547. View

17.

Worrillow L, Travis L, Smith A, Rollinson S, Smith A, Wild C . An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res. 2003; 9(8):3012-20. View

18.

Larson R, Le Beau M . Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact. 2005; 153-154:187-95. DOI: 10.1016/j.cbi.2005.03.023. View

19.

Kaldor J, Day N, Clarke E, van Leeuwen F, Henry-Amar M, Fiorentino M . Leukemia following Hodgkin's disease. N Engl J Med. 1990; 322(1):7-13. DOI: 10.1056/NEJM199001043220102. View

20.

Pedersen-Bjergaard J, Specht L, Larsen S, Ersboll J, Struck J, Hansen M . Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 1987; 2(8550):83-8. DOI: 10.1016/s0140-6736(87)92744-9. View